NIKKEI 225
27,346.88 +19.77 (+0.07%) HANG SENG
22,072.18 +229.85 (+1.05%) CRUDE OIL
76.70 -2.17 (-2.75%) GOLD FUTURES
1,966.80 +21.50 (+1.11%) DOW
34,092.96 +6.92 (+0.02%) BTC-GBP
19,188.30 +570.93 (+3.07%)
Active Biotech AB (publ) (0GQU.L)
| Previous close | 0.0000 |
| Open | 0.0000 |
| Bid | 0.0000 x N/A |
| Ask | 0.0000 x N/A |
| Day's range | 0.0000 - 0.0000 |
| 52-week range | |
| Volume | |
| Avg. volume | N/A |
| Market cap | 1.238M |
| Beta (5Y monthly) | 0.54 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.2520 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Globe Newswire
Successful completion of the first stage of the phase IIa clinical trial of naptumomab in combination with docetaxel and the study is now enrolling into the second stage
Lund, June 1, 2022 - Active Biotech (NASDAQ STOCKHOLM: ACTI) and its partner NeoTX announce today the successful completion of the first stage of a Simon 2 stage phase IIa clinical trial of naptumomab estafenatox (NAP, naptumomab), in combination with docetaxel in patients with advanced or metastatic non-small cell lung cancer (NSCLC) who have been previously treated with chemotherapy and checkpoint inhibitors (CPIs). In the study, the patients are treated with NAP for 4 consecutive days and wit
- Globe Newswire
Annual General Meeting of Active Biotech AB
The Annual General Meeting of Active Biotech was held on May 19, 2022. Due to the situation resulting from the Corona virus, the Meeting was carried out through postal voting, without any physical attendance. The following main resolutions were passed. In accordance with the Board of Directors’ proposal, it was resolved that no dividend would be paid for the financial year 2021, and that the Company’s accumulated loss shall be carried forward. The members of the Board and the CEO were discharged
- Globe Newswire
FDA grants Orphan Drug Designation for tasquinimod in myelofibrosis
Lund May 18, 2022 - Active Biotech AB (Nasdaq Stockholm: ACTI) today announced that the U.S. Food and Drug Administration (FDA) has granted tasquinimod Orphan Drug Designation for the treatment of myelofibrosis. “The Orphan Drug Designation awarded by the FDA for tasquinimod in myelofibrosis represents an important step forward for Active Biotech”, said Helén Tuvesson, CEO Active Biotech. “It opens an important regulatory pathway and provides us with the potential to rapidly advance the developm
